Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
Seeking Alpha

Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Nasdaq

Recursion Pharmaceuticals call volume above normal and directionally bullish

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 7,493 calls trading, 2x expected, and implied vol increasing almost 4 points to 94.34%. Jan-25 6 calls and Jun-25 7 calls are the ...
Hosted on MSN

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript May 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.50273 EPS, expectations ...